Blueprint Medicines - 1792 Exchange

Rating Overview

Blueprint Medicines is Medium Risk.

Blueprint Medicines is Medium Risk. The company often yields to political activism in shaping corporate governance, potentially alienating consumers, dividing employees, and harming shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. The company occasionally embraces corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues at times. This approach fails to safeguard free exercise, free speech, and free enterprise.

Rating Criteria

Corporate Weaponization Risk Levels
Criteria	Risk Level
Cancellations	Lower Risk
Discriminatory Philanthropy	Lower Risk
Employment Protection	High Risk

Corporate Weaponization ⓘ

Corporate Governance and Public Policy Risk Levels
Criteria	Risk Level
Advocacy Bias	High Risk
Funding	Medium Risk
Political Actions	No Data

Corporate Governance and Public Policy ⓘ

Rating Criteria Detail

Criteria Risk Level Rationale

Corporate Weaponization

Criteria:

Has canceled customers, suppliers, or vendors due to their political views or religious beliefs OR corporately boycotts, divests, or sanctions regions, people groups, or industries.

Risk Level:

Lower

Rationale:

Blueprint Medicines has not publicly canceled customers, suppliers, or vendors based on political views or religious beliefs The company believes that when we work together, the impact of our collective efforts can make a profound difference for patients, our employees and the communities where we live and work (1).

Criteria:

Charitable giving (including employee matching programs) policies or practices discriminate against charitable organizations based on views or religious beliefs.

Risk Level:

Lower

Rationale:

Blueprint Medicines does not appear to discriminate against charitable organizations based on views or beliefs “The company believes that when we work together, the impact of our collective efforts can make a profound difference for patients, our employees and the communities where we live and work” (1)(2).

Criteria:

Employment policies fail to protect against viewpoint or other discrimination and/or are ideological in nature.

Risk Level:

High

Rationale:

Blueprint Medicines offers unconscious bias training to its employees (1). Blueprint Medicines is an affirmative action employer. “Blueprint Medicines’ Chief Executive Officer is fully committed to this equal opportunity and affirmative action policy statement and asks for all personnel to assist and support equal employment opportunity for all” (2). The company does not provide viewpoint protections for its employees (3).

Corporate Governance and Public Policy

Criteria:

Uses corporate reputation to support causes, organizations, or policies hostile to freedom of expression.

Risk Level:

High

Rationale:

Blueprint Medicines advocates for abortion. Its CEO, Kate Haviland, signed a letter denouncing the overturning of Roe v. Wade (1). Blueprint Medicines opposed various state and local legislation intended to protect parental rights, girls’ sports, bathroom facilities, and gendered spaces (2). Blueprint Medicines’ CEO Jeff Albers signed MassBio’s Open Letter 2.0, committing the company to implement DEI across various facets of corporate governance including its recruitment, hiring, supply chain, executive compensation, external partnerships, and company programming. Furthermore, signatories are expected to use their influence to promote DEI throughout the company, encourage employees to “self-educate on racism and to contribute to the race dialogue”, and ensure transparency and accuracy of reporting on instances of microaggressions in the workplace while holding leaders accountable for their responses (3)(4)(5). The company supports DEI within its business practices. From its website: “At Blueprint Medicines, we’ve been committed to equity, diversity, and inclusion (ED&I) since our company’s founding in 2011” (6). Blueprint Medicines in 2023, for the second year in a row, the company partnered with OUTbio to host a Pride networking event at its Cambridge office. The event showcased local transgender artist Dani Bernstein, a community service activity with Point of Pride in support of the transgender community, a performance by drag queen Missy Steak, an awareness campaign with Prison Book Program, and more. Blueprint Medicines also sponsored OUTbio’s Pride Reception at BIO (7).

Criteria:

Uses corporate funds to advance ideological causes, organizations, or policies hostile to freedom of expression.

Risk Level:

Medium

Rationale:

Blueprint Medicines provides a benefits package for employees that covers travel costs for an abortion (1). Otherwise, there are no publicly known cases of the company using corporate funds to advance ideological causes, organizations, or policies (2).

Criteria:

Uses corporate political actions and/or financial contributions for ideological, non-business purposes.

Risk Level:

N/A

Rationale:

Blueprint Medicines does not operate a PAC or engage in lobbying at this time (1)(2)(3).